

NASPGHAN Annual Meeting Saturday October 25th, 2014

What's New in the Evaluation and Treatment of Chronic Pancreatitis?

Véronique Morinville MD,CM, FRCP(C)
Pediatric Gastroenterology and Nutrition
Montreal Children's Hospital
McGill University Health Centre
Montreal, QC, Canada

W McGill



I have no conflicts of interest to disclose regarding this presentation

Learning Objectives

- 1. Review of Diagnosis of Pediatric Chronic Pancreatitis (CP)
- 2. Management Options for Pediatric CP
- 3. Emerging Trends, Targets, and Improvements in the Diagnosis and Management of CP

1. Evaluation for Diagnosis of Chronic Pancreatitis

Overview: How are we currently diagnosing CP?

Features of Chronic Pancreatitis

- Progressive inflammatory disease characterized by irreversible structural changes
- Structural changes include:
 - irregular sclerosis; focal or diffuse tissue destruction
 - acinar cell +/or islet cell loss
 - inflammatory cell infiltrates
 - pancreatic duct abnormalities and obstruction
- Can result in irreversible exocrine and/ or endocrine insufficiency

CP: Patient Assessment

- Symptoms, QOL
 - Pain: location, type, frequency, severity
 - Eating, stooling, daily activities
- Physical Examination
 - Nutritional status? masses, tenderness
- Blood, Stool Testing
 - Fecal elastase, vitamins, biochemistry
 - Glucose tolerance test, HgbA1c
 - Functional tests specialized centers

CP: Imaging

- Transabdominal Ultrasound
- "Pancreatic Protocol" CT
- MRI/ MRCP
 - Recent publications with secretin: Sugita R AJR 2014;
 Takahashi AJR 2014; Rustagi T Pancreas 2014; Sandrasegaran K
 Abdom Imaging 2014; Sherman S Gastro 2014
- Endoscopic Ultrasound
- ERCP

Diagnosis Pediatric Chronic Pancreatitis (Clinical + Radiologic +/- Histology)

CP clinical diagnosis via one of the following 3 situations:

- A. Abdominal **Pain** c/w pancreatic origin AND **Imaging** findings suggestive of chronic pancreas damage
- B. Pancreatic **Exocrine Insufficiency** AND suggestive pancreatic **Imaging** findings (careful- CF)
- C. Pancreatic Endocrine Insufficiency AND suggestive pancreatic Imaging findings
- CP may be dx via compatible Histopathology (surgical resection, core Bx)
- Imaging- modalities including CT, MRI/ MRCP, ERCP; transabdo U/S, EUS)

(INSPPIRE Definitions of pediatric pancreatitis, Morinville VD and Husain SZ et al; JPGN 2012)

Search for Causes/ Etiologies CP

- "TIGAR-O" Classification in Adults (Whitcomb 2001)
 - Toxic; Idiopathic; Genetic; Autoimmune; Recurrent and severe acute pancreatitis-associated; Obstructive
- Retrospective Pediatric series:
 - Idiopathic, Traumatic, Biliary including Congenital Malformations, Medication-related, Hereditary-Genetic, Metabolic, Other

Genetics and Pancreatitis: The trypsin-dependent pathologic model of chronic pancreatitis CASR (ECON) Trypsin degradation (acinar cell) Trypsin degradation (acinar cell) PRSS1, SPINK1, CFTR CTRC Acinar cell Inhury AIR PRSS1, SPINK1, CFTR CTRC Acinar cell Acinar cell Acinar cell Trypsin degradation (acinar cell) PRSS1, SPINK1, CFTR CTRC

2. Management Options for CP: What have we been doing?

PAIN #1 symptom affecting QOL Issues of exocrine, endocrine Insufficiency Managing Complications: stones, pseudocysts

Medical Endoscopic Surgical

Pain Management: Traditional "Stepwise" Approach

- Stopping toxins; small meals and supplements
- +/- Pancreatic enzyme supplements, acid suppression
- +/- Antioxidants? (negative: Gastro 2012 ANTICIPATE)
- Analgesics: acetaminophen, NSAIDS; narcotics, centrallyacting agents ("neuropathic"), celiac nerve blocks
- **Endoscopic** therapies: decompression, stones, stents
- Surgical options: decompression, resections
- Dilemma: When do you become more aggressive?
 vs Q. Harm of waiting "too long"?

Surgical Interventions: For Pain, Complications

- Types:
 - Decompression procedures for dilated PD
 - Resections of affected portion of pancreas
 - **Denervation** procedures: le splanchnicectomy
- · Timing of surgery controversial:
 - Q. Does early surgery prevent progression of disease and reduce need for long-term opioid use, or loss of endocrine and exocrine pancreatic function?
 - But: irreversible, complications

Total Pancreatectomy-Islet AutoTransplantation (TP-IAT)

- Rationale TP: Removing all offending tissue to eliminate pancreatitis, inflammation, pain, cancer risk
- Rationale IAT: To preserve islet cells to protect patient from brittle type 3c diabetes
- · Concerns:
 - Irreversible; surgical complications
 - pain relief not always experienced
 - Diabetes protection variable ; need pancreatic enzymes
 - "Exchanging one chronic disease for another"
 - →Specialized centers, criteria

How are we trying to Improve Management?

Recent Publications

Recent Publications: Nutrition/ Medical

- DIET: Effects of Oral Ingestion of the Elemental Diet in Patients with Painful Chronic Pancreatitis in the Real-Life Setting in Japan. Kataoka K et al. Pancreas 2014.
 - Multicenter, prospective; non-random, noncontrol; low fat AA
 - $-\sqrt{1}$ pain reduction, $\sqrt{1}$ improved nutritional indices
- <u>ENZYMES</u>: Pancreatic Enzymes Replacement Therapy in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis: A 1-Year Disease Management Study on Symptom Control and Quality of Life. D'Haese JG et al. Pancreas 2014 (Online).
 - 294 CP and EPI; cohort 1 (already on enzymes) or cohort 2 (not yet on)
 - → Improved symptoms and QOL in both groups at 1y

Recent Publications: Pain Targets

- <u>Pregabalin</u> reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. Olesen SS et al. Gastroenterology 2011.
 - CP: resembles neuropathic pain; 3w; random, double-blind, placebo; 64
 - Pregabalin group → more effective pain relief, improved health status
- Antioxidant therapy for patients with chronic pancreatitis: A systematic review and meta-analysis.
 Zhou D et al. Clin Nutr 2014 (epub)
 - Meta-analysis: 8 studies/573 pxts; antioxidant vs placebo; pain
 - Antioxidants: ↑ pain relief and ↓ need for analgesics; "may be advocated as one medical therapy" for CP

Recent Publications: Are Earlier Interventions Better?

- Endoscopic Management of Early-Stage Chronic Pancreatitis

 Based on M-ANNHEIM Classification System: A Prospective

 Study. He YX et al. Pancreas 2014. (Epub).
 - China; MRCP and CT. M-ANNHEIM staging. improved pain scores at 24m
 - Better imaging → earlier Dx. Earlier tx → improved pain, outcomes
- Systematic Review of <u>Early Surgery</u> for Chronic Pancreatitis: Impact on Pain, Pancreatic Function, and Re-intervention. Yang CJ et al. J Gastrointest Surg 2014 (Epub).
 - 1950 to Jan 2014: Early surgery associated with ↑ complete postoperative pain relief, ↓ pancreatic insufficiency and low re-intervention rates

Recent Publications: Longer-Term Outcomes of Surgeries

- Beger and Frey Procedures for Treatment of Chronic Pancreatitis: Comparison of Outcomes at 16-Year Follow-Up. J Am Coll Surg 2014 (Epub)
 - 74; random to Beger and Frey. Pxt Q. to evaluate long-term survival, QOL, pain, exocrine and endocrine function. Results: No signif diff 16y post
- Is the Whipple procedure harmful for long-term outcome in treatment of chronic pancreatitis? <u>15-years follow-up</u> comparing the outcome after pylorus-preserving pancreatoduodenectomy and Frey procedure in chronic pancreatitis. Bachmann K et al. Ann Surg 2013
 - 64; random to PD and Frey: both providing good/ permanent pain relief; QOL and survival better after Frey after 15y

Recent Publications: ERCP for Pediatric CP

- ERCP in the Management of Pancreatic Diseases in Children.

 Agarwal J et al. GIE 2014.
 - 180 ERCP (range 1-4) in 143 kids; 13.7yo +/- 3.1 (range 5-18)
 - F/u: 64% no pain; 22% improved pain; 2 → surgical drainage
 - → ERCP safe therapeutic option for pancreatic disorders in children in centers with expertise; AE rates comparable to adults
- Efficiency of Pancreatic Duct (PD) <u>Stenting</u> Therapy in Children with Chronic Pancreatitis. G Oracz et al, GIE 2014 (online)
 - 223 PD stents/ 72 kids; esp. hered pancreatitis and PD anatomic abN
 - ↓ # pancreatitis/y : from 1.75 to 0.23. 10 \rightarrow surgery.
 - → ERCP PD stents feasible, safe, effective in CP children

Publications: Pediatric TP-IAT

- Quality of Life Improves for Pediatric Patients After Total Pancreatectomy and Islet Autotransplantation for Chronic Pancreatitis. Bellin MD et al. Clinical Gastro Hepatol 2011.
 - 19 pxt (5-18y) TP-IAT, 2006-2009, Minnesota; severe CP and pain; SF-36 Health Q. pre- and post- surgery; insulin needs
 - Prior surgical drainage → ↓islet yield, ↑ insulin dependence
 - → By 1y post, TP-IAT leading to improved QOL; > 60% insulin-independent or minimal insulin needs

Recent Publications: Pediatric TP-IAT Longer-Term Outcomes

- Long-Term Outcomes of Total Pancreatectomy and Islet Auto Transplantation for Hereditary/ Genetic Pancreatitis.
 Srinath Chinnakotla et al. J Am Coll Surg 2014.
 - 484 TP-IAT from 1977-2012; Minnesota; 80 HGP
 - Post TP-IAT: 90% pancreatitis pain free, sustained pain relief, > 65% partial or full beta-cell function. Improved QOL. Up to 10y fup
 - → Pxts with painful CP due to HGP... high lifetime risk of pancreatic cancer... should be considered earlier for TP-IAT before... inflammation results in ↑ pancreatic fibrosis and ↓ islet cell function"

3. Emerging Trends, Targets, and Improvements in CP Diagnosis and Management

How can we Improve what we Do and what we Could do?

Trends in Diagnosis and Management: **Guidelines**

- Belgian consensus on chronic pancreatitis in adults and children: Statements on diagnosis and nutritional, medical, and surgical treatment. Delhaye M et al; Acta Gastro-Enterologica Belgica 2014.
 - U/S 1st-line imaging CP; MRCP after secretin 2nd step
 - Pediatricians be aware of CP in DDx chronic abdominal pain
 - Attempt to determine etiology: contributory genetic etiology esp. CFTR, SPINK, PRSS1; "CTRC only recently screened"
 - Management conservative; ERCP for strictures and stones

Trends in Diagnosis and Management: Further Understanding of Genetics

- CFTR, SPINK1, CTRC and PRSS1 variants in chronic pancreatitis: is the role of mutated CFTR overestimated?
 Rosendahl J et al; Gut 2013.
- Variants in CPA1 are strongly associated with earlyonset chronic pancreatitis. Witt H et al. Nat Genet 2013. CPA1= carboxypeptidase A1
- Mechanisms of CFTR functional variants that impair regulated bicarbonate permeation and increase risk for pancreatitis but not for cystic fibrosis. LaRusch J et al. PLOS Genetics 2014.

Trends in Studying CP: Multicenter Consortia

• INSPPIRE Consortium (Description: Morinville and Lowe et al, JPGN 2014)

	n (%)*
CP patients with history of ≥1 episode acute pancreatitis	73 (96%)
Risk factors for pancreatitis	
Genetic	51 (67%)
PRSS1	33 (43%)
SPINK1	.14 (19%)
CFTR	11 (14%)
CTRC	2 (3%)
Autommune	3 (4%
Obstructive	25 (33%)
Pancreas divisum	15 (20%)
Sphincter of Oddi dysfunction	3 (196)
Galistones	3 (4%)
Pancreatic duct maturion	2 (3%)
Pancreatic duct obstruction	1 (1%)
Other	5 (7%)
Toxic/metabolic	8 (11%)
Alcohol (MD determined)	1 (1%)
Passive smoking (exposure)	3 (4%)
Hyperlipidemia	1 (1%)
Medication	1 (1%)
Metabolic disease	1 (1%)
Other	1 (1%)
None cred	8711%

Treatment modalities	n (%) tried
Medications (n=63)	
Pancreatic enzymes (for	
pain or recurrent	
pancreattis)*	47 (75%)
Anti-oxidants/ vitamins	14 (22%)
Steroids for autoimmune	
pancreattis	3 (5%)
Octreotide	2 (3%)
Procedures (n=76)	
Any ERCP	55 (72%)
Pancreatic	
sphinclerotomy	45 (59%)
Binary sphinclerotomy	21 (28%)
Pancreatic stent	35 (46%)
Biliary stent	4 (5%)
Stone removal	19 (25%)
Celiac plexus block	3 (4%)
Surgery (n=76)	
Cholecystectomy	15 (20%)
Lateral	
pancreaticojejonstomy	11 (14%)
Partial pancreafectomy	1 (1%)
Total pancreatectomy +	
islet autotransplant	21 (28%)

CP Database Sept 2012- Aug 2013: Etiologies; Treatments

Trends: Early Surgery vs Step-up? Providing Evidence for What To Do

- Early surgery versus optimal current step-up practice for chronic pancreatitis (ESCAPE): design and rationale of a randomized trial. Ali, Usama Ahmed et al. for the Dutch Pancreatitis Study Group. BMC Gastroenterology 2013.
 - CP management: conservative step-up; "burn-out" hypothesis
 - But now evidence: prolonged periods pain → peripheral and central nerve sensitization → self-perpetuating pain state
 - Thus Plan → Randomized, controlled, parallel, multicenter trial to see if early surgical intervention will benefit in terms of better pain control and preservation of pancreatic function

Trends: TP-IAT Guidelines

 Total pancreatectomy and islet autotransplantation in chronic pancreatitis: Recommendations from

PancreasFest. Bellin MD et al, for the PancreasFest Recommendation Conference Participants. Pancreatology 2014.

- Rationale: Lack of clear guidance on TP-AIT
- 5 major areas req clinical evaluation and management addressed:
 - 1. Indications for TPAIT
 - 2. Contraindications
 - ${\bf 3.\ Optimizing\ timing\ of\ procedure}\\$
 - 4. Need for multi-disciplinary team and roles of members
 - 5. Life-long management of issues following TPIAT including diabetes monitoring and nutrition evaluation

Disease burden	
(number of	
respondents)	
Pattern of abdominal	
pain (59)	n (%)
Usually pain free, with	n (%)
episodes of mild to	
moderate pain	10 (17%)
Usually pain free, with	10 (17:9)
episodes of severe pain	21 (36%)
Constant mild to	21 (30.9)
moderate pain	2 (3%)
Constant mild to	2 (5/4)
moderate pain, plus	
episodes of severe pain	22 (37%)
Constant severe pain	4 (7%)
Mean pain scores (scale	4 (1.0)
0-100)	median (IQ range)
Constant pain (15)	55 (30, 78)
Episodic pain (50)	80 (62, 94)
Number of	median (IQ range)
ER visits lifelong (48)	5 (3, 14)
ER visits last year (47)	3 (1.5)
Hospitalizations lifelong	
(52)	5.5 (2.5, 14.5)
Hospitalizations last	
year (48)	2 (1, 3)
Days of school missed	
past 1 month (47)	3 (0, 8)
*Pancreatic	
insufficiency (55)	n (%)
Exocrine insufficient	19 (34%)
Endocrine insufficient [®]	1 (1%)
*Excludes post-total pance	reatectomy; *1 patie
with diabetes prior to total	al pancreatectomy.

Trends in Studying CP: Prospective Studies?

INSPPIRE Database Sept 1, 2012 - Aug 31, 2013

Disease Burden: Pain and Insufficiencies

→To help Study QOL, Natural History

Future Targets? Immune-based Therapy

- Immune cells and immune-based therapy in pancreatitis. Xue J et al. Immunol Res 2014; 58: 378-386.
 - Pancreatic stellate cells (PSC) –synthesis, degradation of extracellular matrix proteins; activated PSC in CP
 - Macrophages, mast, CD4+,CD8+ T-cells implicated PSC activ'n
 - →Inhibiting PSC activation ... Q. prevent panc inflammation and
- Imbalance of wnt/dkk negative feedback promotes persistent activation of pancreatic stellate cells in chronic pancreatitis. Hu Y. PLoS One 2014; 9(4): e95145
 - Wnt signaling may mediate profibrotic effect of PSC activation
 Wnt2/Dkk-1 potential therapeutic targets for CP?

Future Targets?

The NEW ENGLAND JOURNAL of MEDICINE

PETABLICHED IN 181

NOVEMBER 3, 2011

VOL. 365 NO. 18


A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation

Bonnie W. Ramsey, M.D., Jane Davies, M.D., M.B., Ch.B., N. Gerard McElvaney, M.D., Elizabeth Tullis, M.D., Scott C. Bell, M.B., B.S., M.D., Pavel Dřevinek, M.D., Matthias Griesa, M.D., Edward F. McKone, M.D., Claire E. Wainwright, M.D., M.B., B.S., Michael W. Korstan, M.D., Richard Moss, M.D., Felix Rajsen, M.D., Ph.D., Isabelle Sermet-Caudelus, M.D., Ph.D., Steven M. Rowe, M.D., M.S.P., Qumming Dong, Ph.D., Sally Rodriguez, M.S., Karl Yen, M.D., Claudia Ordohez, M.D., and J. Stuart Elborn, M.D., for the VX08-770-102 Study Group*

Targets: CFTR Potentiation

- G551D missense mutation: affects function of CFTR channels at cell surface
- Ivacaftor (VX-770) increases time that activated CFTR channels at cell surface remain open ("potentiator")
 → ↑ chloride- transport activity
- Study: Improved FEV1/ lung function, weight gain; decreased pulm exacerbations
- Improved sweat Cl- testing:

What about Use in Pancreatitis?



Q. CAN WE "CORRECT" or at least IMPROVE FUNCTIONALITY of mutated proteins esp. CFTR?

Slide courtesy of Dr. DC Whitcomb; certain data from Whitcomb DC. Annu Rev Med. 2010;61:413-24.

Summary: What is New in Diagnosis and Treatment of Pediatric CP?

- Diagnosis: Definitions, Status, Imaging
- Genetic factors: +++ Present in CP
- Multi-center Databases → Better descriptions of patients, disease burden
- Therapies: More pediatric experience; globalization; more objective evaluations of timing and efficacy of interventions

Summary: Pediatric Chronic Pancreatitis The Future

- Improved Care: more Individualized Therapy
- Pediatric Experience rather than Extrapolation
- Multi-Center Prospective Trials
- Evidence-Based Interventions
- New and Future Targets: Immune Response/ anti-fibrosis; Potentiators for genetic defects

Thank you